New pain relieving drug doing well in phase 11 trials
I subscribe to a biotech investment notification service and Corgantechs new adjunct therapy is showing progress in stage 11 clinical trials. When new single use drug Corgantech "4975" demonstrated its ability to provide relief of acute and chronic pain to patients experiencing post-surgical, neuropathic and musculoskeletal pain for weeks to months after only a single, local administration used in conjuction with opiate therapy provides better pain relief without any additional opiate side effects.
Unlike opioids, which have systemic side effects including nausea, vomiting, constipation and respiratory depression, 4975 appears to have a more favorable safety profile.
Just a heads ups. I imagine more can be found by checking the manufacturers web site news and press release section.
Have a happy happy, Dave